; Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis Review
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis Review

VIEWS: 32 PAGES: 41

Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Algeta ASA (Algeta) is a pharmaceutical company with focus on the development therapies for cancer, bas

More Info
  • pg 1
									         Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH82497FSA                                                                                          Publication Date: MAY 2013

          PO Box 54, Kjelsas                                 Phone              +47 23 007990                   Revenue          627.39 (million NOK)
          Oslo, Ostlandet                                    Fax                +47 23 007991                   Net Profit       235.37 (million NOK)
          0411                                               Website            www.algeta.com                  Employees        105
                                                                                ALGETA [Oslo         Stock                       Pharmaceuticals           &
          Norway                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Algeta ASA (Algeta) is a pharmaceutical company with focus on the development therapies for cancer, based on its alpha-
       pharmaceutical platform. The company's lead product, Alpharadin, targets bone metastases that occur mostly in major cancers
       such as hormone-refractory prostate cancer, lung, breast and kidney cancers. It is being developed and commercialized under an
       agreement with Bayer Pharma AG. Alpharadin completed Phase III clinical trials in treating bone metastasis resulting from
       castration-resistant prostate cancer (CRPC).
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Algeta ASA, SWOT Analysis
         Dr. Kapil Dhingra                   Director                                 Strengths                              Weaknesses
         Joseph Anderson                     Director
                                                                                      Lead Product Candidate –               Operating Inefficiency
         Lars Abrahmsen                      Senior    Vice   President,              Alpharadin
                                             Protein Therapeutics
                                                                                      Alpha-Pharmaceutical Platform
         Dr. Donald Coppen                   Director,              Business
                                             Development
         Mike Booth                          Senior   Vice     President,             Opportunities                          Threats
                                             Communications          and
                                             Corporate Affairs                        New R&D Program                        Uncertainty in R&D Activities
        Source: Annual Report, Company Website, Primary and Secondary                 The Bayer AG Agreement                 Delay in the Planned Clinical
        Research, GlobalData
                                                                                                                             Trials
       Share Data
         Algeta ASA                                                                  Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Share Price (NOK) as on 24-                                      209
        May-2013
        EPS (NOK)                                                        5.47
        Market Cap (million NOK)                                       8,888
        Enterprise Value (million NOK)                                 8,520
        Shares Outstanding (million)                                       43
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 15, 2013         Algeta Reports Revenue Of NOK70.6m In Q1
                                                                                                           2013
                                                                                      Feb 28, 2013         Algeta Reports Revenue Of NOK627m In 2012
                                                                                      Nov 22, 2012         Algeta And Ablynx Enter Into Research
                                                                                                           Collaboration To Evaluate New Alpha-
                                                                                                           Pharmaceuticals
                                                                                      Nov 15, 2012         Algeta Reports Revenue Of NOK59.5m In Q3
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis                                                                    Reference Code: GDPH82497FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Algeta ASA - Key Facts ...................................................................................................................................................................... 5
       Algeta ASA - Key Employees ............................................................................................................................................................. 6
       Algeta ASA - Major Products and Services ........................................................................................................................................ 7
       Algeta ASA - Pharmaceutical Pipeline Products Data ........................................................................................................................ 8
          Algeta ASA, Pipeline Products by Therapy Area ............................................................................................................................ 8
          Algeta ASA, Pipeline Products by Development Phase .................................................................................................................. 9
       Algeta ASA - History ......................................................................................................................................................................... 11
       Algeta ASA - Company Statement ................................................................................................................................................... 13
       Algeta ASA - Locations And Subsidiaries ......................................................................................................................................... 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Algeta ASA - Business Description .................................................................................................................................................. 16
       Algeta ASA - Corporate Strategy...................................................................................................................................................... 17
       Algeta ASA - SWOT Analysis ........................................................................................................................................................... 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          Algeta ASA - Strengths ................................................................................................................................................................. 18
             Strength - Lead Product Candidate – Alpharadin ...................................................................................................................... 18
             Strength - Alpha-Pharmaceutical Platform ................................................................................................................................ 18
             Strength - Global Clinical Operations ........................................................................................................................................ 18
          Algeta ASA - Weaknesses ............................................................................................................................................................ 18
             Weakness - Operating Inefficiency ............................................................................................................................................ 18
          Algeta ASA - Opportunities ........................................................................................................................................................... 19
             Opportunity - New R&D Program .............................................................................................................................................. 19
             Opportunity - The Bayer AG Agreement ................................................................................................................................... 19
             Opportunity - Fast Track Designation: Alpharadin..................................................................................................................... 19
             Opportunity - Market Potential: Oncology.................................................................................................................................. 19
          Algeta ASA - Threats .................................................................................................................................................................... 19
             Threat - Uncertainty in R&D Activities ....................................................................................................................................... 19
             Threat - Delay in the Planned Clinical Trials ............................................................................................................................. 20
             Threat - Competition and Technological Changes .................................................................................................................... 20
       Algeta ASA - Key Competitors ......................................................................................................................................................... 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27
          Algeta ASA, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013.......................................................................... 27


Algeta ASA (ALGETA) - Financial and Strategic SWOT Analysis                                                                                                    Reference Code: GDPH82497FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Algeta ASA, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ..........
								
To top